Morning infusions may boost lung cancer treatment
NCT ID NCT06882174
First seen Jan 07, 2026 · Last updated May 08, 2026 · Updated 19 times
Summary
This study tests whether giving immunotherapy (pembrolizumab) in the morning works better than giving it at any random time for people with advanced non-small cell lung cancer. About 58 participants will be split into two groups: one gets infusions only between 8-10 AM, the other gets them at standard times. The goal is to see if morning timing improves how long the cancer stays under control, and if this approach is practical for a larger future study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.